United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News CureVac stock surges as BioNTech announces strategic mRNA-focused acquisition BioNTech acquires CureVac in a $1.25B all-stock deal to expand its mRNA cancer pipeline. Includes stock insights, premium terms, and investor sentiment. byPallavi MadhirajuJune 12, 2025